Twin Focus Capital Partners’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Twin Focus Capital Partners’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-10,000	Closed	-$426K	–	98
2015 Q3	$426K	Buy	+10,000	New	+$483K	0.54%	41
2015 Q2	–	Sell	-10,000	Closed	-$380K	–	107
2015 Q1	$380K	Hold	10,000	–	–	0.3%	51
2014 Q4	$283K	Buy	+10,000	New	+$278K	0.33%	64

Other funds holding PTLA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Twin Focus Capital Partners's PTLA Position: Q4 2015 in Review

Twin Focus Capital Partners sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2015, closing a stake of 10,000 shares — an estimated $426K sold.

Twin Focus Capital Partners first reported a position in PTLA in Q4 2014 and held it in 3 quarters. The position peaked at $426K in Q3 2015. 190 funds tracked by Wall St. Rank hold PTLA as of Q4 2015.

Twin Focus Capital Partners reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
Twin Focus Capital Partners sold 10,000 Portola Pharmaceuticals, Inc. shares in Q4 2015, an estimated $426K.
Twin Focus Capital Partners first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 3 quarters.
Twin Focus Capital Partners's Portola Pharmaceuticals, Inc. position peaked at $426K in Q3 2015.
190 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2015.

Based on Twin Focus Capital Partners's 13F filing for Q4 2015, filed 16 Feb 2016.